AR087829A1 - Combinaciones que comprenden fingolimod y un compuesto antidepresivo - Google Patents

Combinaciones que comprenden fingolimod y un compuesto antidepresivo

Info

Publication number
AR087829A1
AR087829A1 ARP120103335A ARP120103335A AR087829A1 AR 087829 A1 AR087829 A1 AR 087829A1 AR P120103335 A ARP120103335 A AR P120103335A AR P120103335 A ARP120103335 A AR P120103335A AR 087829 A1 AR087829 A1 AR 087829A1
Authority
AR
Argentina
Prior art keywords
compound
antidepressive
combinations
fingolimod
pharmaceutically acceptable
Prior art date
Application number
ARP120103335A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR087829A1 publication Critical patent/AR087829A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una combinación que comprende fingolimod en forma libre, en forma de sal farmacéuticamente aceptable o en forma de derivado fosfato, y por lo menos un compuesto antidepresivo o una sal farmacéuticamente aceptable del mismo y opcionalmente, por lo menos un vehículo farmacéuticamente aceptable, para el uso simultáneo, separado o sucesivo.
ARP120103335A 2011-09-13 2012-09-11 Combinaciones que comprenden fingolimod y un compuesto antidepresivo AR087829A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161534126P 2011-09-13 2011-09-13

Publications (1)

Publication Number Publication Date
AR087829A1 true AR087829A1 (es) 2014-04-23

Family

ID=46826510

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103335A AR087829A1 (es) 2011-09-13 2012-09-11 Combinaciones que comprenden fingolimod y un compuesto antidepresivo

Country Status (11)

Country Link
US (1) US20140228402A1 (es)
EP (1) EP2755644A1 (es)
JP (1) JP2014526484A (es)
KR (1) KR20140069120A (es)
AR (1) AR087829A1 (es)
AU (1) AU2012307535A1 (es)
BR (1) BR112014005626A2 (es)
CA (1) CA2846768A1 (es)
MX (1) MX2014002965A (es)
RU (1) RU2014114500A (es)
WO (1) WO2013037713A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140072879A (ko) * 2011-08-31 2014-06-13 아마켐 엔브이 신규한 약한 rock 억제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004251636B2 (en) * 2003-05-27 2006-11-09 Merz Pharma Gmbh & Co. Kgaa Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
US20100093672A1 (en) * 2007-05-04 2010-04-15 Yves-Alain Barde Use of s1p receptor modulator

Also Published As

Publication number Publication date
RU2014114500A (ru) 2015-10-20
JP2014526484A (ja) 2014-10-06
WO2013037713A1 (en) 2013-03-21
AU2012307535A1 (en) 2014-04-03
MX2014002965A (es) 2014-07-09
US20140228402A1 (en) 2014-08-14
CA2846768A1 (en) 2013-03-21
BR112014005626A2 (pt) 2017-03-28
KR20140069120A (ko) 2014-06-09
EP2755644A1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
AR077629A1 (es) Mimetico de smac
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
CL2014002915A1 (es) Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico.
AR094193A1 (es) Productos de higiene bucal que comprenden oxido de zinc y trimetilglicina
CL2013003650A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo anti leucocidina luke y un portador farmaceuticamente aceptable.
JP2014501485A5 (es)
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
AR102203A1 (es) Composiciones para el cuidado oral que comprenden zinc, arginina y serina
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
DOP2013000236A (es) Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
EA201491609A1 (ru) Модуляторы x рецепторов печени
ECSP13013094A (es) Composiciones de limpieza de sal colina
CL2014000552A1 (es) Uso de 4,4´-[fluoro-(1h-1,2,4-triazol-1-il)metileno]bisbenzonitrilo para el tratamiento del hipogonadismo y composicion farmaceutica oral que comprende al compuesto y kit farmaceutico que comprende a la composicion.
JP2013536184A5 (es)
CL2013002193A1 (es) Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno.
GT201400042A (es) Compuesto de benzotiazolona
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
AR087829A1 (es) Combinaciones que comprenden fingolimod y un compuesto antidepresivo

Legal Events

Date Code Title Description
FB Suspension of granting procedure